Corneal Cross-Linking: The Science Beyond the Myths and Misconceptions.


Journal

Cornea
ISSN: 1536-4798
Titre abrégé: Cornea
Pays: United States
ID NLM: 8216186

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 19 3 2019
medline: 18 6 2019
entrez: 19 3 2019
Statut: ppublish

Résumé

There has been a recent explosion in the variety of techniques used to accomplish corneal cross-linking (CXL) for the treatment of ectatic corneal diseases. To understand the success or failure of various techniques, we review the physicochemical basis of corneal CXL and re-evaluate the current principles and long-standing conventional wisdom in the light of recent, compelling, and sometimes contradictory research. Two clinicians and a medicinal chemist developed a list of current key topics, controversies, and questions in the field of corneal CXL based on information from current literature, medical conferences, and discussions with international practitioners of CXL. Standard corneal CXL with removal of the corneal epithelium is a safe and efficacious procedure for the treatment of corneal ectasias. However, the necessity of epithelium removal is painful for patients, involves risk and requires significant recovery time. Attempts to move to transepithelial corneal CXL have been hindered by the lack of a coherent understanding of the physicochemistry of corneal CXL. Misconceptions about the applicability of the Bunsen-Roscoe law of reciprocity and the Lambert-Beer law in CXL hamper the ability to predict the effect of ultraviolet A energy during CXL. Improved understanding of CXL may also expand the treatment group for corneal ectasia to those with thinner corneas. Finally, it is essential to understand the role of oxygen in successful CXL. Improved understanding of the complex interactions of riboflavin, ultraviolet A energy and oxygen in corneal CXL may provide a successful route to transepithelial corneal CXL.

Identifiants

pubmed: 30882538
doi: 10.1097/ICO.0000000000001912
doi:

Substances chimiques

Cross-Linking Reagents 0
Photosensitizing Agents 0
Collagen 9007-34-5
Riboflavin TLM2976OFR

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

780-790

Auteurs

Roy S Rubinfeld (RS)

Department of Ophthalmology, Georgetown University Medical Center/Washington Hospital Center, Washington, DC.
Re:Vision Private Practice, Rockville, MD.

Ciro Caruso (C)

Corneal Transplant Centre, Pellegrini Hospital, Naples, Italy.

Carmine Ostacolo (C)

Department of Pharmacy, University Federico II of Naples, Naples, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH